MVIR:STO
Medivir AB
SEK 1.72
arrow_upward
+1.77%(+0.030) 1D
Jun 5, 1:42:03 PM GMT+2 · SEK
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEK 1.70
High
SEK 1.78
Low
SEK 1.69
Mkt. cap
928.69M
Avg. vol.
3.01M
Volume
1.33M
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.54
Shares outstanding
538.67M
No. of employees
7
Open
SEK 1.70
High
SEK 1.78
Low
SEK 1.69
Mkt. cap
928.69M
Avg. vol.
3.01M
Volume
1.33M
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.54
Shares outstanding
538.67M
No. of employees
7
News stories
From sources across the web
Stock Titan
·
4 minutes ago
YY Group's AI work marketplace wins award as SE Asia hotels face staff crunch
GlobeNewswire
·
14 minutes ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus
·
28 minutes ago
Brand Engagement Network (NASDAQ: BNAI) Invests $1 Million in Ac
Barron's
·
14 minutes ago
S&P 500 Futures Fall in Premarket Trading; ServiceTitan, First American Financial Lead
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
AI content may include mistakes. Learn more